These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29704557)

  • 1. Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts.
    Kahl M; Settele F; Knick P; Haupts U; Bosse-Doenecke E
    Protein Expr Purif; 2018 Sep; 149():51-65. PubMed ID: 29704557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid optimization and prototyping for therapeutic antibody-like molecules.
    Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
    MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
    Schoonooghe S; Burvenich I; Vervoort L; De Vos F; Mertens N; Grooten J
    Protein Eng Des Sel; 2010 Sep; 23(9):721-8. PubMed ID: 20616115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
    Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
    MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Antibodies on the Surface of CHO Cells.
    Nguyen AW; Le K; Maynard JA
    Methods Mol Biol; 2020; 2070():397-422. PubMed ID: 31625108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward Drug-Like Multispecific Antibodies by Design.
    Sawant MS; Streu CN; Wu L; Tessier PM
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Bifunctional Antibodies with Constant Region Fusion Architectures.
    Du J; Cao Y; Liu Y; Wang Y; Zhang Y; Fu G; Zhang Y; Lu L; Luo X; Kim CH; Schultz PG; Wang F
    J Am Chem Soc; 2017 Dec; 139(51):18607-18615. PubMed ID: 29186655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of orthogonal Fab-based trispecific antibody formats.
    Wu X; Yuan R; Bacica M; Demarest SJ
    Protein Eng Des Sel; 2018 Jul; 31(7-8):249-256. PubMed ID: 29718394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
    Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ
    Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities.
    Yanakieva D; Pekar L; Evers A; Fleischer M; Keller S; Mueller-Pompalla D; Toleikis L; Kolmar H; Zielonka S; Krah S
    MAbs; 2022; 14(1):2018960. PubMed ID: 35014603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs.
    Condado-Morales I; Dingfelder F; Waibel I; Turnbull OM; Patel B; Cao Z; Rose Bjelke J; Nedergaard Grell S; Bennet A; Hummer AM; Raybould MIJ; Deane CM; Egebjerg T; Lorenzen N; Arosio P
    MAbs; 2024; 16(1):2403156. PubMed ID: 39364796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments.
    Fagète S; Botas-Perez L; Rossito-Borlat I; Adea K; Gueneau F; Ravn U; Rousseau F; Kosco-Vilbois M; Fischer N; Hartley O
    Protein Eng Des Sel; 2017 Sep; 30(9):575-582. PubMed ID: 28444391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.